



DRUG DISCOVERY

Predictive ADME and Toxicology Strategies

Challenges and opportunities for in vivo, in vitro and in silico predictive technologies

By Dr. Nelesh Patel

 [Table of Contents](#)

Dr. Nelesh Patel, B.Sc., Ph.D.

Dr. Nelesh Patel, a former Post-Doctoral Research Associate and Healthcare Analyst, has acquired more than 8 years experience in scientific research and has built relationships/contacts with major medical device/biotechnology and pharmaceutical companies. Dr. Patel is currently set-up as an independent consultant specializing in the production of custom and syndicated market intelligence deliverables to a range of medical device, pharmaceutical and biotechnology markets. His current research projects include orthopedic medical devices, the role of nanotechnology in medicine and emerging trends in drug discovery.

Dr. Patel has published more than 15 scientific peer reviewed journal papers and has delivered award-winning presentations at medical device/biotechnology conferences. He graduated with a BS.c (Hons) in Biomedical Materials Science from the University of Manchester and a PhD in Orthopedic Medical Devices from the University of Cambridge.

Copyright © 2006 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Predictive ADME and Toxicology Strategies

Executive Summary	10	
Introduction to predictive ADME/Tox screening	10	
Traditional methods of ADME/Tox testing	11	
Novel <i>in vitro</i> and <i>in vivo</i> predictive models	12	
<i>In silico</i> ADME/Tox	13	
Chapter 1	Introduction to predictive ADME/Tox screening	16
Summary		16
Objectives and scope of report		17
Overview		17
A historical review of the drug discovery process		18
Drug attrition rates in preclinical and clinical testing phases		22
The importance of ADME/Tox testing		25
Early ADME studies		27
Current market landscape		27
Market challenges		29
Market drivers and restraints		30
Chapter 2	Traditional methods of ADME/Tox testing	34
Summary		34
Introduction		35
Absorption		35
Distribution		39
Metabolism		39
Excretion		42

Toxicity testing	43
Physiochemical characterization and stability	44
Conventional <i>in vitro</i> ADME/Tox screening methods	46
Caco-2	46
MDCK	48
CYP 450 and hepatic microsomes	48
Paracellular markers, MTT test, and LDH test	49
Conventional <i>in vivo</i> ADME/Tox models	50
Radiolabels	51
Cassette dosing	51
Semi-simultaneous dosing	52
Limitations of traditional <i>in vitro</i> and <i>in vivo</i> ADME/Tox screening methods	54

Chapter 3 Novel *in vivo* and *in vitro* predictive models 56

Summary	56
Introduction	57
<i>In vitro</i> screening	58
Cultured cells	59
Membrane vesicles (BBMV, BLMV)	59
Caco-2 Cells	59
Madin-Darby Canine Kidney (MDCK) Model	60
HT29	61
T84 and IEC-18 cell lines	61
Immobilized Artificial Membrane (IAM) Columns	62
Parallel Artificial Membrane Permeation Assay (PAMPA)	62
P-Glycoprotein (PGP)-drug transporter	63
Solubility	63
Log P	64
Plasma protein binding	64
Toxicity	64
Automated and high throughput <i>in vitro</i> ADME/Tox screening	66
Millipore 96-well filter-based assays and the Hamilton Microlab Star liquid handling workstation	66
MultiScreen Caco-2 Assay System	67
LeadStream	68
Hurel Microfluidic Circuit	69
NanoStream CL system	70
NanoMate and ESI chip system	71
RapidFire Lead Discovery System	72
The Biomek FX system	72
B-Clear, Accutate and AccuPro systems	73
Liquid handling systems	74
<i>In vivo</i> models	74

<i>Drosophila</i>	75
<i>C. elegans</i>	76
Rodent models	77
Zebrafish models	80
Competitive structure	83
Company profiles	85
Aclara Biosciences	85
Advion Biosciences	86
Agilent Technologies	87
Amphioxus Cell Technologies	87
Applied Biosciences	87
BD Biosciences	88
BioTrove Inc.	88
Caliper Life Sciences	89
Covance	89
DanioLabs	90
Eksigent Technologies	91
Gene Logic	91
Hurel Corporation	92
LGC Limited	92
Nanostream Inc.	93
NemaRx Pharmaceuticals Inc.	93
Nimbus Biotechnology	93
Novascreen	93
Perkin Elmer	94
Phylonix	94
Qualyst	95
Tecan	95
Thermo Electron Corp.	96
Xenogen	96
Zygogen	97
Zyomyx	97
Market analysis	97
<i>In vitro</i> ADME/Tox screening market	97
<i>In vivo</i> ADME/Tox market	99

Chapter 4 ***In silico* predictive models** **102**

Summary	102
Introduction	103
Current technologies	104
Mathematical methods	105
Oral bioavailability	106
Solubility	106
Blood-brain barrier penetration	107
Absorption/membrane permeability	107
Toxicity	108

Metabolism	108
Physicochemical properties	109
“Global” and “Local” models	109
Commercially available products	110
GastroPlus™	112
ADMET Modeler™	113
DDDPlus™	115
ADMET Predictor™	115
DEREK for Windows	117
Meteor	119
Vitic	119
Accord for Excel	119
Cerius ² ADME/Tox Package	120
ACD/LogD Suite and ACD/LogD Sol Suite	121
Metabolite ID™	121
AurScope® ADME/DDI	122
Bio-Loom™	122
KnowItAll™	122
Pallas Software Family	124
HazardExpert™	125
MetabolExpert™	125
ToxAlert™	125
MDL Metabolite™ Database	126
MDL Toxicity™ Database	126
MetaDrug™	126
VolSurf™	126
MetaSite™	127
Emerging technologies	127
Factors limiting the impact of <i>in silico</i> ADME/Tox models	130
Competitive structure	132
Company profiles	132
Accelrys	132
Applied Biosystems	133
Aureus Pharma	133
BG Medicine	133
BioByte Corporation	134
BioKin Limited	134
Bio-Rad Laboratories	135
ChemSilico	135
Chenomx	135
ComGenex Inc.	136
CompuDrug	136
Cyprotex	136
Elsevier MDL	137
GeneGo	137
Leadscope	138
LHASA Limited	138
Molecular Discovery Ltd.	139
Pharma Algorithms	139

	Simulations Plus	140
	Market analysis	140
Chapter 5	Appendix	144
	Research methodology	144
	Abbreviations and acronyms	145
	Index	148

List of Figures

Figure 1.1:	The major phases of drug discovery	19
Figure 1.2:	The drug discovery phase of a typical project aimed at producing a drug	20
Figure 1.3:	Typical success rates at each step of drug discovery and development	23
Figure 1.4:	Factors that cause the failure of potential drug candidates	24
Figure 1.5:	ADME/Tox market challenges	29
Figure 1.6:	ADME/Tox market challenges	30
Figure 3.1:	The Hamilton Microlab Star Liquid Handling System	67
Figure 3.2:	MultiScreen Caco-2 Assay System Components	68
Figure 3.3:	The LeadStream system	69
Figure 3.4:	The NanoStream LC system	70
Figure 3.5:	ESI Biochip	71
Figure 3.6:	The Biomek FX Laboratory Automation Workstation	72
Figure 3.7:	VivoVision system for retn-luc expression in male and female mice	79
Figure 3.8:	Utility of the Zebrafish model in drug design	80
Figure 3.9:	<i>In vitro</i> ADME/Tox revenue forecasts, 2004-2012	98
Figure 3.10:	<i>In vivo</i> ADME/Tox revenue forecasts, 2004-2012	100
Figure 4.11:	ADMET Modeler™ overview	114
Figure 4.12:	ADMET Predictor™ screen shot	117
Figure 4.13:	KnowItAll concept	123
Figure 4.14:	<i>In silico</i> ADME/Tox revenue forecasts	141

List of Tables

Table 2.1:	Typical experiments to assess the ADME properties of potential drug candidates	45
Table 2.2:	Percentage of pharmacokinetic studies by <i>in vivo</i> model	50
Table 3.1:	<i>In vitro</i> and <i>in vivo</i> ADME/Tox companies and products, A-M	84
Table 3.2:	<i>In vitro</i> and <i>in vivo</i> ADME/Tox companies and products, N-Z	85
Table 3.3:	<i>In vitro</i> ADME/Tox revenues, 2004-2012	98
Table 3.4:	<i>In vivo</i> ADME/Tox revenues, 2004-2012	99
Table 4.5:	Mathematical models for predictive ADME/Tox	105
Table 4.6:	Advantages and disadvantages of “global” predictive models	109
Table 4.7:	Advantages and disadvantages of “local” predictive models	110
Table 4.8:	Commercially available <i>in silico</i> ADME/Tox products	111
Table 4.9:	<i>In silico</i> ADME/Tox revenues, 2004-2010	140